Medicenna Therapeutics announces upcoming presentation at AACR meeting

Medicenna Therapeutics announced the publication of an abstract that has been accepted for a poster presentation at the American Association for Cancer Research, AACR, Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 – 19, 2023. Poster Title: "Characterization of MDNA132, an IL-13 Decoy Receptor Selective Superkine for Targeted Delivery of Immunotherapies to the Tumor Microenvironment." The poster will describe preclinical studies characterizing a long-acting version of MDNA132 and BiSKITs, comprising MDNA132 fused to an IL-2 super-agonist or anti-PD1 antibody. MDNA132 is an IL-13 Superkine designed to enable targeted delivery of immunotherapies to the tumor microenvironment. MDNA132 exhibits high affinity and selectivity for the IL13Ralpha2, which is highly overexpressed in various tumors such as pancreatic, prostate, bladder, colorectal, breast and lung cancer but minimally expressed in healthy tissues.